Protein kinase C beta in the tumor microenvironment promotes mammary tumorigenesis

Frontiers in Oncology

Volumn 4 APR, Issue , 2014, Pages

  Wallace, Julie A ^a   Pitarresi, Jason R ^a   Sharma, Nandini ^a   Palettas, Marilly ^a   Cuitiño, Maria C ^a   Sizemore, Steven T ^a,b   Yu, Lianbo ^a,b   Sanderlin, Allen ^a   Rosol, Thomas J ^a,c   Mehta, Kamal D ^a   Sizemore, Gina M ^a   Ostrowski, Michael C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Fibroblasts; Mammary neoplasms (experimental); Protein kinase C beta; Stroma; Tumor microenvironment

Indexed keywords

KI 67 ANTIGEN; PROTEIN KINASE C BETA; VIRUS MIDDLE T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FIBROBLAST; HISTOLOGY; IMMUNOFLUORESCENCE TEST; MACROPHAGE; MALE; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

EID: 84901041552     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00087     Document Type: Article

References (62)

1. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer (2007) 7(4):281-94. doi: 10.1038/nrc2110.
2. Ono Y, Kikkawa U, Ogita K, Fujii T, Kurokawa T, Asaoka Y, et al. Expression and properties of two types of protein kinase C: alternative splicing from a single gene. Science (1987) 236(4805):1116-20. doi:10.1126/science.3576226.
3. Kawakami T, Kawakami Y, Kitaura J. Protein kinase C beta (PKC beta): normal functions and diseases. J Biochem (2002) 132(5):677-82. doi:10.1093/oxfordjournals.jbchem.a003273.
4. Bosco R, Melloni E, Celeghini C, Rimondi E, Vaccarezza M, Zauli G. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem (2011) 11(3):185-99. doi:10.2174/138955711795049899.
5. Borner C, Wyss R, Regazzi R, Eppenberger U, Fabbro D. Immunological quantitation of phospholipid/Ca2+-dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors. Int J Cancer (1987) 40(3):344-8. doi:10.1002/ijc.2910400310.
6. O'Brian C, Vogel VG, Singletary SE, Ward NE. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res (1989) 49(12):3215-7.
7. Gordge PC, Hulme MJ, Clegg RA, Miller WR. Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur J Cancer (1996) 32A(12):2120-6. doi:10.1016/S0959-8049(96)00255-9.
8. Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, et al. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest (1995) 95(4):1906-15. doi:10.1172/JCI117872.
9. Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase C alpha. Clin Cancer Res (2001) 7(10):3156-65.
10. Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC. Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer (2000) 83(6):782-91. doi:10.1054/bjoc.2000.1326.
11. Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S. Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure. Br J Cancer (2003) 88(9):1400-2. doi:10.1038/sj.bjc.6600923.
12. Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene (2006) 25(23):3286-95. doi:10.1038/sj.onc.1209361.
13. Lonne GK, Cornmark L, Zahirovic IO, Landberg G, Jirstrom K, Larsson C. PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer (2010) 9:76. doi:10.1186/1476-4598-9-76.
14. Kim J, Thorne SH, Sun L, Huang B, Mochly-Rosen D. Sustained inhibition of PKCalpha reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene (2011) 30(3):323-33. doi:10.1038/onc.2010.415.
15. Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF, Nicholson RI. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol (2007) 60(11):1216-21. doi:10.1136/jcp.2006.041616.
16. McKiernan E, O'Brien K, Grebenchtchikov N, Geurts-Moespot A, Sieuwerts AM, Martens JW, et al. Protein kinase C delta expression in breast cancer as measured by real-time PCR, western blotting and ELISA. Br J Cancer (2008) 99(10):1644-50. doi:10.1038/sj.bjc.6604728.
17. Pan Q, Bao LW, Kleer CG, Sabel MS, Griffith KA, Teknos TN, et al. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res (2005) 65(18):8366-71. doi:10.1158/0008-5472.CAN-05-0553.
18. Masso-Welch PA, Winston JS, Edge S, Darcy KM, Asch H, Vaughan MM, et al. Altered expression and localization of PKC eta in human breast tumors. Breast Cancer Res Treat (2001) 68(3):211-23. doi:10.1023/A:1012265703669.
19. Karp G, Abu-Ghanem S, Novack V, Mermershtain W, Ariad S, Sion-Vardy N, et al. Localization of PKCeta in cell membranes as a predictor for breast cancer response to treatment. Onkologie (2012) 35(5):260-6. doi:10.1159/000338443.
20. Ali S, Al-Sukhun S, El-Rayes BF, Sarkar FH, Heilbrun LK, Philip PA. Protein kinases C isozymes are differentially expressed in human breast carcinomas. Life Sci (2009) 84(21-22):766-71. doi:10.1016/j.lfs.2009.03.007.
21. Gokmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, et al. Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Res Treat (2010) 124(2):327-35. doi:10.1007/s10549-010-0733-2.
22. Li H, Weinstein IB. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res (2006) 66(23):11399-408. doi:10.1158/0008-5472.CAN-06-2386.
23. Awadelkarim KD, Callens C, Rosse C, Susini A, Vacher S, Rouleau E, et al. Quantification of PKC family genes in sporadic breast cancer by qRT-PCR: evidence that PKCiota/lambda overexpression is an independent prognostic factor. Int J Cancer (2012) 131(12):2852-62. doi:10.1002/ijc.27600.
24. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature (2004) 432(7015):332-7. doi:10.1038/nature03096.
25. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest (1996) 98(9):2018-26. doi:10.1172/JCI119006.
26. Yoshiji H, Kuriyama S, Ways DK, Yoshii J, Miyamoto Y, Kawata M, et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res (1999) 59(17):4413-8.
27. Suzuma K, Takahara N, Suzuma I, Isshiki K, Ueki K, Leitges M, et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA (2002) 99(2):721-6. doi:10.1073/pnas.022644499.
28. Su TT, Guo B, Kawakami Y, Sommer K, Chae K, Humphries LA, et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol (2002) 3(8):780-6. doi:10.1038/ni823.
29. Saijo K, Mecklenbrauker I, Santana A, Leitger M, Schmedt C, Tarakhovsky A. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J Exp Med (2002) 195(12):1647-52. doi:10.1084/jem.20020408.
30. Shinohara H, Kurosaki T. Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling. Immunol Rev (2009) 232(1):300-18. doi:10.1111/j.1600-065X.2009.00836.x.
31. Goicoechea SM, Garcia-Mata R, Staub J, Valdivia A, Sharek L, McCulloch CG, et al. Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts. Oncogene (2013) 33(10):1265-73. doi:10.1038/onc.2013.68.
32. Bluwstein A, Kumar N, Leger K, Traenkle J, Oostrum J, Rehrauer H, et al. PKC signaling prevents irradiation-induced apoptosis of primary human fibroblasts. Cell Death Dis (2013) 4:e498. doi:10.1038/cddis.2013.15.
33. Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, Kemp BE, et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes (2003) 52(2):512-8. doi:10.2337/diabetes.52.2.512.
34. Meier M, Park JK, Overheu D, Kirsch T, Lindschau C, Gueler F, et al. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes (2007) 56(2):346-54. doi:10.2337/db06-0891.
35. Bansode RR, Huang W, Roy SK, Mehta M, Mehta KD. Protein kinase C deficiency increases fatty acid oxidation and reduces fat storage. J Biol Chem (2008) 283(1):231-6. doi:10.1074/jbc.M707268200.
36. Huang W, Bansode R, Mehta M, Mehta KD. Loss of protein kinase C beta function protects mice against diet-induced obesity and development of hepatic steatosis and insulin resistance. Hepatology (2009) 49(5):1525-36. doi:10.1002/hep.22815.
37. Leitges M, Schmedt C, Guinamard R, Davoust J, Schaal S, Stabel S, et al. Immunodeficiency in protein kinase cbeta-deficient mice. Science (1996) 273(5276):788-91. doi:10.1126/science.273.5276.788.
38. Wolford CC, McConoughey SJ, Jalgaonkar SP, Leon M, Merchant AS, Dominick JL, et al. Transcription factor ATF3 links host adaptive response to breast cancer metastasis. J Clin Invest (2013) 123(7):2893-906. doi:10.1172/JCI64410.
39. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol (1992) 12(3):954-61.
40. Soule HD, McGrath CM. A simplified method for passage and long-term growth of human mammary epithelial cells. In vitro Cell Dev Biol (1986) 22(1):6-12. doi:10.1007/BF02623435.
41. Wallace JA, Li F, Balakrishnan S, Cantemir-Stone CZ, Pecot T, Martin C, et al. Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer. PLoS One (2013) 8(8):e71533. doi:10.1371/journal.pone.0071533.
42. Abramoff MD, Magalhães PJ, Ram SJ. Image processing with ImageJ. Biophotonics Int (2004) 11:36-42.
43. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 449(7162):557-63. doi:10.1038/nature06188.
44. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol (2003) 163(5):2113-26. doi:10.1016/S0002-9440(10)63568-7.
45. Manni A, Buckwalter E, Etindi R, Kunselman S, Rossini A, Mauger D, et al. Induction of a less aggressive breast cancer phenotype by protein kinase C-alpha and -beta overexpression. Cell Growth Differ (1996) 7(9):1187-98.
46. Gibby K, You WK, Kadoya K, Helgadottir H, Young LJ, Ellies LG, et al. Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan. Breast Cancer Res (2012) 14(2):R67. doi:10.1186/bcr3174.
47. Pickup MW, Laklai H, Acerbi I, Owens P, Gorska AE, Chytil A, et al. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-beta-deficient mouse mammary carcinomas. Cancer Res (2013) 73(17):5336-46. doi:10.1158/0008-5472.CAN-13-0012.
48. Szabova L, Chrysovergis K, Yamada SS, Holmbeck K. MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene (2008) 27(23):3274-81. doi:10.1038/sj.onc.1210982.
49. Ricciardelli C, Frewin KM, Tan Ide A, Williams ED, Opeskin K, Pritchard MA, et al. The ADAMTS1 protease gene is required for mammary tumor growth and metastasis. Am J Pathol (2011) 179(6):3075-85. doi:10.1016/j.ajpath.2011.08.021.
50. Grum-Schwensen B, Klingelhofer J, Grigorian M, Almholt K, Nielsen BS, Lukanidin E, et al. Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. Cancer Res (2010) 70(3):936-47. doi:10.1158/0008-5472.CAN-09-3220.
51. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 16(2):91-102. doi:10.1016/j.ccr.2009.06.018.
52. Vasiljeva O, Papazoglou A, Kruger A, Brodoefel H, Korovin M, Deussing J, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res (2006) 66(10):5242-50. doi:10.1158/0008-5472.CAN-05-4463.
53. Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 115(5):1163-76. doi:10.1172/JCI23424.
54. Lam JB, Chow KH, Xu A, Lam KS, Liu J, Wong NS, et al. Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyMT mice by modulation of phosphatase and tensin homolog activities. PLoS One (2009) 4(3):e4968. doi:10.1371/journal.pone.0004968.
55. Landskroner-Eiger S, Qian B, Muise ES, Nawrocki AR, Berger JP, Fine EJ, et al. Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res (2009) 15(10):3265-76. doi:10.1158/1078-0432.CCR-08-2649.
56. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med (2008) 6:11. doi:10.1186/1741-7015-6-11.
57. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia (2002) 7(2):177-89. doi:10.1023/A:1020304003704.
58. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev (2006) 25(3):315-22. doi:10.1007/s10555-006-9001-7.
59. Baay M, Brouwer A, Pauwels P, Peeters M, Lardon F. Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol (2011) 2011:565187. doi:10.1155/2011/565187.
60. Sledge GW Jr., Gokmen-Polar Y. Protein kinase C-beta as a therapeutic target in breast cancer. Semin Oncol (2006) 33(3 Suppl 9):S15-8. doi:10.1053/j.seminoncol.2006.03.019.
61. Mina L, Krop I, Zon RT, Isakoff SJ, Schneider CJ, Yu M, et al. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. Invest New Drugs (2009) 27(6):565-70. doi:10.1007/s10637-009-9220-1.
62. Clemons M, Joy AA, Abdulnabi R, Kotliar M, Lynch J, Jordaan JP, et al. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. Breast Cancer Res Treat (2010) 124(1):177-86. doi:10.1007/s10549-010-1152-0.